Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study

BACKGROUND: This phase I multicenter study was designed to evaluate the safety, tolerability, efficacy, and translational effects on the tumor microenvironment of itacitinib (Janus-associated kinase 1 (JAK1) inhibitor) in combination with epacadostat (indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor)...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Powderly, John D, Nemunaitis, John J, Luke, Jason J, Mansfield, Aaron S, Messersmith, Wells A, Sahebjam, Solmaz, LoRusso, Patricia M, Garrido-Laguna, Ignacio, Leopold, Lance, Geschwindt, Ryan, Ding, Kai, Smith, Michael, Berlin, Jordan D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921936/
https://www.ncbi.nlm.nih.gov/pubmed/35288468
http://dx.doi.org/10.1136/jitc-2021-004223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921936/
https://www.ncbi.nlm.nih.gov/pubmed/35288468
http://dx.doi.org/10.1136/jitc-2021-004223

Ejemplares similares